Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2014-03-24 Investor Presentation
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Investor Presentation 51 pages 2.0MB
Investor Presentation Classification · 100% confidence The document is titled 'Admedus Investor Presentation March 2014' and contains detailed information about the company's business overview, products, market potential, and strategic direction. It includes forward-looking statements, product descriptions, market snapshots, and pipeline details. There is no indication that this is a formal financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a regulatory filing or certification. The content is consistent with a presentation aimed at investors to inform them about the company's business and prospects. The length is substantial (15,000 characters), and the content is typical of an Investor Presentation (IP). Therefore, the correct classification is Investor Presentation (IP).
2014-03-24 English
Appendix 3B - Options & Notice under Section 708A 15 pages 740.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard announcement for the exercise of options and the allotment of new shares by a company listed on the Australian Stock Exchange (ASX). It details the number of shares issued, exercise price, and compliance with ASX listing rules. The document is a regulatory announcement about a capital change (exercise of options and allotment of shares), not a financial report or earnings release. It is not a full report but a formal notification of a share issue event. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a mere report publication announcement or a regulatory filing fallback. Confidence is high due to the clear identification of the document as an Appendix 3B new issue announcement and detailed share issue information.
2014-03-06 English
Half Yearly Report and Accounts 29 pages 146.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled as a 'Half Yearly Report (Appendix 4D) for the 6 months ended 31 Dec 2013' and contains detailed financial information including revenue, loss, cash balance, directors' report, financial report, directors' declaration, and audit report. It covers the half-year period ending 31 December 2013, which is a period shorter than a full fiscal year. The document includes substantive financial data and analysis, such as revenue figures, loss before tax, net tangible assets, and operational highlights. It also includes a consolidated half-year financial report and directors' commentary. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. The document is not merely an announcement or a certification, but a full report. Therefore, the correct classification is IR with high confidence. H1 2014
2014-02-25 English
Admedus's CardioCel Cleared for Sale in the US 2 pages 279.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Admedus Ltd dated 10th February 2014. It announces FDA clearance for the company's product CardioCel to be marketed in the US, highlighting the commercial and regulatory milestone. The content focuses on product approval, market expansion, and company growth prospects. There are no financial statements, quarterly or annual results, nor any detailed financial data or management discussion of financial performance. The document is a corporate announcement about a regulatory approval and market development rather than a financial report or management discussion. It is not a report publication announcement since it does not mention any report being attached or published. Therefore, the best fitting category is a Regulatory Filing (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2014-02-09 English
Admedus Herpes Interim Phase I Results 2 pages 277.7KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement from Admedus Ltd dated February 3, 2014, reporting interim Phase 1 clinical trial results for a therapeutic vaccine for Herpes Simplex Virus (HSV-2). It highlights that the study met its primary safety endpoint and detected a T-cell response, with further analysis ongoing. The document is a public announcement of clinical trial progress and results, not a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis, nor is it a regulatory filing or certification. The content focuses on clinical trial interim results, which is typical for a capital/financing update or clinical progress announcement. Given the nature of the announcement about study results and progress, it best fits the category of Capital/Financing Update (CAP), as it relates to the company's development pipeline and potential future value creation. The document length (5695 characters) and content confirm it is a substantive announcement rather than a brief notice or report publication announcement.
2014-02-02 English
Appendix 4C - quarterly 7 pages 396.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C - Quarterly Report' and is addressed as an announcement to the Australian Stock Exchange. It contains detailed financial data including consolidated cash flow statements for the quarter ended 31 December 2013 and year-to-date figures, as well as narrative on company activities and financing events during the quarter. The presence of actual financial statements and substantive financial data for a period shorter than a full fiscal year (quarterly) indicates this is a comprehensive interim/quarterly report. The document is 9346 characters long, which is sufficient to be the report itself rather than a mere announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2014
2014-01-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.